日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

The Costs of Home Monitoring by Telemedicine vs Standard Care for Inflammatory Bowel Diseases-A Danish Register-Based, 5-Year Follow-up Study

远程医疗居家监测与炎症性肠病标准治疗的成本比较——一项基于丹麦登记数据的5年随访研究

期刊:Journal of Crohns & Colitis
影响因子:8.7
doi:10.1093/ecco-jcc/jjae120
Al-Sheikh, Marwah; Ankersen, Dorit Vedel; Olsen, Jens; Spanggaard, Maria; Peters-Lehm, Charlotte T; Naimi, Rahim M; Bennedsen, Mette; Burisch, Johan; Munkholm, Pia
炎症/感染
炎症
发表日期：2025
文献求助 收藏

Multiomics Identifies Potential Molecular Profiles Associated With Outcomes After BRAF-Targeted Therapy in Patients With BRAF V600E-Mutated Advanced Solid Tumors

多组学鉴定出与BRAF V600E突变晚期实体瘤患者接受BRAF靶向治疗后预后相关的潜在分子特征

期刊:Jco Precision Oncology
影响因子:5.6
doi:10.1200/PO.24.00266
Eriksen, Martina; Hansen, Anne M; Nielsen, Annelaura B; Mundt, Filip; Mann, Matthias; Lassen, Ulrik; Ahlborn, Lise B; Højgaard, Martin; Spanggaard, Iben; Qvortrup, Camilla; Yde, Christina W; Rohrberg, Kristoffer S
BRAF
发表日期：2025
文献求助 收藏

Pemigatinib for previously treated metastatic or unresectable central nervous system tumors with fibroblast growth factor receptor mutations or rearrangements: FIGHT-207 results

培米替尼用于既往接受过治疗且存在成纤维细胞生长因子受体突变或重排的转移性或不可切除的中枢神经系统肿瘤：FIGHT-207 研究结果

期刊:Oncologist
影响因子:4.2
doi:10.1093/oncolo/oyaf272
Spanggaard, Iben; Matrana, Marc; Rocha Lima, Caio; Mahipal, Amit; Vieito, Maria; Hervieu, Alice; Goyal, Lipika; Rodón, Jordi; Veronese, Maria Luisa; Oliveira, Natalia; Li, Xin; Schaffer, Michael; Kesari, Santosh
成纤维细胞
肿瘤
肿瘤免疫
信号转导
神经科学
细胞生物学
发表日期：2025
文献求助 收藏

Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor)

实体瘤免疫调节：RO6870810（BET抑制剂）和atezolizumab（PD-L1抑制剂）的1b期研究

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-025-13851-4
Marbach, Daniel; Brouer-Visser, Jurriaan; Brennan, Laura; Wilson, Sabine; Davydov, Iakov I; Staedler, Nicolas; Duarte, José; Martinez Quetglas, Iris; Nüesch, Eveline; Cañamero, Marta; Chesné, Evelyne; Au-Yeung, George; Hamilton, Erika; Lheureux, Stephanie; Richardson, Debra L; Spanggaard, Iben; Gomes, Bruno; Franjkovic, Izolda; DeMario, Mark; Kornacker, Martin; Lechner, Katharina
PD-L1
免疫/内分泌
发表日期：2025
文献求助 收藏

Mutational Landscape Assessed in Tumor Tissue and Circulating Tumor DNA During Treatment of Patients with HER2/ERBB2-Mutated Solid Tumors

在HER2/ERBB2突变型实体瘤患者治疗过程中，评估肿瘤组织和循环肿瘤DNA中的突变图谱

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-025-14599-7
Egebjerg, Kristian; Spanggaard, Iben; Ahlborn, Lise Barlebo; Rohrberg, Kristoffer Staal; Harsloef, Laurine; Hoejgaard, Martin; Schmidt, Ane Yde; Lassen, Ulrik; Tuxen, Ida Viller; Hasselby, Jane Preuss; Rossing, Maria; Santoni-Rugiu, Eric; Yde, Christina Westmose; Mau-Sørensen, Morten
ERBB2
肿瘤
肿瘤免疫
HER2
发表日期：2025
文献求助 收藏

Mapping MAGE-A4 expression in solid cancers for targeted therapies

绘制实体瘤中 MAGE-A4 表达图谱以进行靶向治疗

期刊:Frontiers in Oncology
影响因子:3.3
doi:10.3389/fonc.2025.1484182
Habigt, Christin; Rottey, Sylvie; Spanggaard, Iben; Lopez, Juanita S; Garralda, Elena; Calvo, Emiliano; Bechter, Oliver; Desai, Jayesh; Galot, Rachel; Gandhi, Leena; Heil, Florian; Rieder, Natascha; Dimitrov, Ivan; Quetglas, Iris Martinez; Heichinger, Christian; Keshelava, Nino; Roller, Andreas
MAG
发表日期：2025
文献求助 收藏

Actionable alterations in glioblastoma: Insights from the implementation of genomic profiling as the standard of care from 2016 to 2023

胶质母细胞瘤中可操作的改变：从2016年到2023年基因组分析作为标准治疗方案的实施中获得的启示

期刊:Neuro-Oncology Practice
影响因子:2.5
doi:10.1093/nop/npae082
Fougner, Vincent; Urup, Thomas; Poulsen, Hans Skovgaard; Grunnet, Kirsten; Westmose, Christina Yde; Melchior, Linea Cecilie; Larsen, Karen Bonde; Højgaard, Martin; Spanggaard, Iben; Belcaid, Laila; Rohrberg, Kristoffer Staal; Lassen, Ulrik; Hasselbalch, Benedikte; Nørøxe, Dorte Schou
细胞生物学
发表日期：2025
文献求助 收藏

Treating intrahepatic cholangiocarcinoma with pemigatinib: two case reports of Nordic patients

使用培米替尼治疗肝内胆管癌：两例北欧患者的病例报告

期刊:Acta Oncologica
影响因子:2.2
doi:10.2340/1651-226X.2025.42073
Väliaho, Vesa T; Spanggaard, Iben
肿瘤
胆管癌
肿瘤免疫
发表日期：2025
文献求助 收藏

Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial

出版商更正：Pemigatinib 用于既往接受过治疗且存在 FGFR1-FGFR3 激活突变的实体瘤：FIGHT-207 篮式试验（II 期）

期刊:Nature Medicine
影响因子:50
doi:10.1038/s41591-024-03072-w
Rodón, Jordi; Damian, Silvia; Furqan, Muhammad; García-Donas, Jesús; Imai, Hiroo; Italiano, Antoine; Spanggaard, Iben; Ueno, Makoto; Yokota, Tomoya; Veronese, Maria Luisa; Oliveira, Natalia; Li, Xin; Gilmartin, Aidan; Schaffer, Michael; Goyal, Lipika
FGFR3
FGFR1
发表日期：2024
文献求助 收藏

Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial

Pemigatinib 用于既往接受过治疗且存在 FGFR1-FGFR3 激活突变的实体瘤：FIGHT-207 II 期篮式试验

期刊:Nature Medicine
影响因子:50
doi:10.1038/s41591-024-02934-7
Rodón, Jordi; Damian, Silvia; Furqan, Muhammad; García-Donas, Jesús; Imai, Hiroo; Italiano, Antoine; Spanggaard, Iben; Ueno, Makoto; Yokota, Tomoya; Veronese, Maria Luisa; Oliveira, Natalia; Li, Xin; Gilmartin, Aidan; Schaffer, Michael; Goyal, Lipika
FGFR3
FGFR1
发表日期：2024
文献求助 收藏